Ekterly
What Ekterly is used for
Ekterly is indicated for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Ekterly
- Active substance
- sebetralstat
- Disease area
- Angioedemas, Hereditary
- Medicine group
- Other hematological agents
- ATC code
- B06AC08
- Marketing authorisation holder
- Kalvista Pharmaceuticals (Ireland) Limited
- Authorised in the EU since
- 2025
Official information
In the USA
Same active substance: Ekterly
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Ekterly used for?
Ekterly is indicated for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older.
What is the active substance in Ekterly?
Ekterly contains sebetralstat.
Who makes Ekterly?
The EU marketing authorisation holder is Kalvista Pharmaceuticals (Ireland) Limited.
Is Ekterly an orphan medicine?
Yes. Ekterly is designated an orphan medicine in the EU, for a rare disease (Angioedemas, Hereditary).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU